Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer
NCT ID: NCT01615965
Last Updated: 2015-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
160 participants
INTERVENTIONAL
2010-02-28
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer
NCT06657131
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
NCT03789253
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy
NCT00373035
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
NCT07131956
Early Detection of Prostate Cancer
NCT04556916
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
micrometastases
Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
tumor marker detection in lymph nodes
tumor marker detection in lymph nodes by quantitative PCR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tumor marker detection in lymph nodes
tumor marker detection in lymph nodes by quantitative PCR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Locally operable tumor
* Negative bone scan (obligatory if Gleason Score \> 7 or PSA \> 20ng/ml
* Karnofsky ≥ 80%
* Age 18 - 75 years
* Informed consent in written form
* Sufficient hematologic, coagulatory and renal function
* Compliant patient and geographic precondition for adequate follow-up given
Exclusion Criteria
* Organ metastases on CT-scan /MRI or in Histology
* Myocardial infarction or stroke within the last 6 months
* Severe cardiovascular (Grade III - IV according to NYHA), pulmonary (pO2 \< 60 mmHg), renal, hepatic oder hematopoetic impairment
* Severe active or chronic infection (z.B. pos. HIV-Antibody-Test, HBs-Ag-detected in Serum and/ or chronic Hepatitis)
* Severe psychiatric disease
* Previous chemotherapy
* Previous pelvine radiotherapy
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technical University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urologic Department
Munich, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2607/09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.